TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03114176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Diet consisted of a very low carbohydrate ketogenic diet (for 7 days) with the use of some phytoextracts as previously described. The consumed diet was primarily made of beef and veal, poultry, fish, raw and cooked green vegetables without restrictions, cold cuts (dried beef, carpaccio and cured ham), eggs and seasoned cheese (e.g., parmesan). The allowed drinks were infused tea, moka coffee and herbal extracts. The foods and drinks that subjects had to avoid included alcohol, bread, pasta, rice, milk, yogurt, soluble tea, and barley coffee. To facilitate adherence to the nutritional regime, a variety of special meals based on protein and fibers were given to each subject. KD characteristics are protein intake 1.3g/kg/day, to maintain skeletal muscle mass; carbohydrates intake less than 40 g/day and 50-60% of total kcal to induce ketosis. In accordance with a hypocaloric profile, total energy intake was calculated with 200 kcal more than basal metabolic rate.
Study: NCT01308008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home exercise/physical activity (PA) enhancement program with behavioral support
Description: Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: flex and toning health education program
Description: Initial flex and toning program continued on follow-up along with health education
Study: NCT00535561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate tablets 325 mg, po, TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate plus levothyroxine
Description: Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
Study: NCT00784420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453,061
Description: UK-453,061 1000 mg once daily for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UK-453,061
Description: UK-453,061 1000 mg once daily for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400 mg twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg twice daily for 10 days
Study: NCT03992508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent pneumatic compression

Intervention type: PROCEDURE
Group type: OTHER
Intervention: complex decongestive therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: complex decongestive therapy
Study: NCT02892474

Intervention type: PROCEDURE
Intervention: Hybrid Coronary Revascularization (HCR)
Description: Hybrid coronary revascularization (HCR) is a combination of surgery and catheter procedures to open up clogged heart arteries. HCR is the intentional combination of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The HCR strategy combines grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with PCI of non-LAD coronary stenoses. Drug-eluting stents are substituted for saphenous vein grafts (SVG) for non-LAD coronary targets, and the surgical LIMA to LAD bypass is performed, ideally through a minimally invasive, limited access, sternal-sparing approach.

Intervention type: PROCEDURE
Intervention: Coronary Artery Bypass Grafting (CABG)
Description: Coronary artery bypass grafting (CABG) is a surgery to create a new path for blood flow to the heart. A healthy section of vein or artery from elsewhere in the patient's body will be attached to the coronary artery just above and below the area of concern, to create a way for blood to bypass the blocked part of the coronary artery.
Study: NCT02011321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Description: clevidipine infusion x4 hours
Study: NCT02655432

Intervention type: DEVICE
Intervention: Spot photoscreener
Description: Screening of vision problem through an automated device

Intervention type: PROCEDURE
Intervention: Ophthalmologic evaluation
Description: Screening of vision problem through an ophthalmologic evaluation

Intervention type: PROCEDURE
Intervention: Cyclopleged refraction
Description: Screening of refractive problems through a cyclopleged optometric refraction
Study: NCT01735487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg
Study: NCT00198380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg/day, until progression or severe toxicity
Study: NCT01033734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir [Tamiflu]
Description: 5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
Study: NCT03428893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: Participants will receive usual care physical therapy guided by Clinical Practice Guidelines and based on individual symptoms and need over 7 in-person visits. Measures will be collected by the physical therapist related to leg strength, balance, fitness, and mobility as part of the usual care physical therapy evaluation and follow-up. The treating physical therapist will negotiate the physical therapy intervention based on patient preferences and goals and assessment findings. Using clinical practice guidelines, the intervention for the research participants is expected to address deficits in strength, mobility, balance, and cardiovascular endurance. Exercise prescription will be provided using the Wellpepper physical therapy exercise prescription mobile app.
Study: NCT00639483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
Study: NCT02388438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bongener
Study: NCT04176263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBT
Description: The SBT group will receive a 4-week split-belt treadmill training, 3 times a week using a standardized progression protocol. The sessions, including breaks, will approximately take 1 hour each. The training will be given by a trainer experienced with PD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TBT
Description: The TBT group will receive a 4-week tied-belt treadmill training, 3 times a week. To make sure exposure of the two interventions is similar the sessions of the TBT group will be of similar length and progression level (approximately 1 hour each). The training will be given by a trainer experienced with PD.
Study: NCT03080298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03095742

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Low MAP
Description: Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High MAP
Description: Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
Study: NCT04640272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBM-007
Description: Intravitreal injection
Study: NCT03487575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open trial
Description: Integrated electronic support and care support manager contact
Study: NCT02409589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG
Description: The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surface prediction length method
Description: The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.
Study: NCT02538874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02831413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RS+
Description: The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RS+
Description: The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Codeacademy
Description: a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
Study: NCT04548726

Intervention type: DEVICE
Intervention: Sapien 3 Transcather Aortic Valve Implant
Description: Implant of a Ballon Expandable Aortic Valve Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis via a transcatheter procedure.

Intervention type: DEVICE
Intervention: Myval Transcather Aortic Valve Implant
Description: Implant of a Ballon Expandable Aortic Valve Myval (Meril Life Sciences Pvt. Ltd., India) prosthesis via a transcatheter procedure.
Study: NCT02070029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture Therapy - Initial Evaluation History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood.~Physical Exam: inspection of tongue and palpation of central and peripheral pulses.~Chinese Diagnoses for Female Sexual Dysfunction: Kidney Yang Deficiency; Liver Qi Stagnation; Generalized Blood Deficiency; Spleen Yang Deficiency; Heart Fire~- Subsequent Sessions 25 minute sessions, twice weekly, for 5 weeks = total 10 sessions Needle usage = 8-20, average 14 per session Typically placed on the scalp, lower abdomen, elbows and knees
Study: NCT03057236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Coping Skills
Description: The CBCS-HCV is a psychosocial intervention delivered in group format. Through 9 group sessions, patients will learn coping skills, relaxation techniques and other new cognitive and behavioral skills based on several empirically-supported cognitive behavioral interventions.
Study: NCT03443908

Intervention type: DEVICE
Intervention: CPAP
Description: CPAP therapy 3-4 weeks
Study: NCT00822965

Intervention type: OTHER
Intervention: Questionnaires
Description: 3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.

Intervention type: OTHER
Intervention: Phone Interviews
Description: 2 follow-up phone interviews.

Intervention type: BEHAVIORAL
Intervention: Educational Packet
Description: Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
Study: NCT00530894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN Transcatheter Heart Valve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN Transcatheter Heart Valve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Valve Replacement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical management and/or balloon aortic valvuloplasty
Study: NCT01081912

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, no active substance, shells identical to active comparator capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone bitartrate
Description: dosage form: capsule~Strengths 10mg, 20mg, 30mg, 40mg, 50mg
Study: NCT03578471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without NR and BF
Description: Each participant will be fitted with the Noise Reduction (NR) and Beamforming (BF) disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR
Description: Each participant will be fitted with the Noise Reduction (NR)(Sound Changing) program on the same hearing aid. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The Noise Reduction is working spatially independent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with BF
Description: Each participant will be fitted with a beam forming program on the same hearing aid. Beam forming (BF) principle is a sound processing algorithm to remove noise from certain directions to improve the speech intelligibility and comfort.
Study: NCT02340585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Generation Neuroform Stent System
Description: The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
Study: NCT01418807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRANSVAGINAL SPECIMEN EXTRACTION
Description: Transvaginal specimen retrieval following posterior colpotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRANSUMBILICAL SPECIMEN EXTRACTION
Description: Transumbilical specimen retrieval following enlargement of the umbilical port
Study: NCT02238275

Intervention type: DRUG
Intervention: Micardis® plus
Study: NCT02330159

Intervention type: PROCEDURE
Intervention: Novel Wound Healing Protocol
Description: All patients will undergo surgical excision of the pilonidal disease and application of the novel wound healing protocol. After excision, MatriStem MicroMatrix powder will be applied to the wound bed. A MatriStem Multilayer Wound Matrix sheet will then be placed over the MatriStem MicroMatrix, secured in place, then covered with surface dressings. The wound should be left undisturbed for 10-14 days (until the 1st follow-up visit). At the 1st postoperative visit, the wound will reassessed, and a second application of the MicroMatrix to the wound bed may be performed. At subsequent follow-up visits at 1, 3, and 6 months, the wound bed will be measured, photo documentation will be captured, and patients will complete a survey to assess quality of life.
Study: NCT01263483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and voglibose
Description: Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and voglibose
Description: Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voglibose
Description: Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
Study: NCT03237377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg via IV infusion every 4 weeks for up to 3 doses/cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg via IV infusion every 4 weeks for up to 3 doses/cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75mg via IV infusion every 4 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation
Description: 5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation
Description: 5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lobectomy
Description: patients may proceed to surgery post drug and radiation intervention for lung lobectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lobectomy
Description: patients may proceed to surgery post drug and radiation intervention for lung lobectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care adjuvant chemotherapy
Description: patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care adjuvant chemotherapy
Description: patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery
Study: NCT01028092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti R-IL2 + Cyclosporine
Description: * anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin + Everolimus
Description: * Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti R-IL2 + Cyclosporine then Everolimus
Description: * anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0~* cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6
Study: NCT03868592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric sleeve/bariatric surgery
Description: weight loss
Study: NCT03087630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reasoned-Based Intervention
Description: Receives personalized feedback based on the reasoned pathway of the Prototype Willingness Model.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-Based Intervention
Description: Receives personalized feedback based on the social pathway of the Prototype Willingness Model.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Intervention
Description: Receives personalized feedback based on both the reasoned and social pathways of the Prototype Willingness Model.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control
Description: Receives personalized feedback related to nutrition and exercise, unrelated to drinking behavior.